How are Proto Oncogenes Targeted in Cancer Therapy?
Targeting proto oncogenes has become a significant focus in cancer therapy. Drugs such as tyrosine kinase inhibitors (TKIs) and monoclonal antibodies are designed to specifically inhibit the activity of oncogenic proteins. For instance, trastuzumab (Herceptin) is a monoclonal antibody that targets the HER2 receptor, effectively treating HER2-positive breast cancer. Histological analysis of tumor samples can help determine the presence and level of proto oncogene expression, guiding personalized treatment strategies.
